Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,602.60GBp
2:25pm BST
Change (% chg)

12.20 (+0.77%)
Prev Close
1,590.40
Open
1,593.00
Day's High
1,602.80
Day's Low
1,589.40
Volume
3,284,915
Avg. Vol
8,526,807
52-wk High
1,612.80
52-wk Low
1,235.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.21
Market Cap(Mil.): £75,181.28
Shares Outstanding(Mil.): 4,918.63
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 38.75 30.93 32.76
EPS (TTM): 0.39 -- --
ROI: 7.58 15.07 14.61
ROE: 278.84 16.59 16.33

Commodities slide pulls FTSE to three-and-a-half month closing low

LONDON Britain's top share index sank on Wednesday as emerging markets stress and a sharp selloff in commodities drove down stocks across Europe, with investors running scared after trade spat deepened between Turkey and the United States.

15 Aug 2018

Long-acting injection a shot in the arm for GSK's HIV business

LONDON A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business.

15 Aug 2018

UPDATE 2-Long-acting injection a shot in the arm for GSK's HIV business

* GSK hopes to gain market share from market leader Gilead (Updates with latest GSK and Gilead share price moves)

15 Aug 2018

Britain's FTSE steadies as GSK leads health stocks, miners weigh

LONDON, Aug 15 The UK's top share index steadied on Wednesday as a fall across mining stocks capped results-driven gains, with GlaxoSmithKline a standout riser after the result of a clinical trial boosted hopes for its HIV business.

15 Aug 2018

Long-acting injection a shot in the arm for GSK's HIV business

LONDON A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business.

15 Aug 2018

Orchard raises $150 million to expand after GSK gene therapy deal

LONDON Anglo-American biotech company Orchard Therapeutics has raised a further $150 million (117.7 million pounds) to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million (109.8 million pounds).

13 Aug 2018

Orchard raises $150 million to expand after GSK gene therapy deal

LONDON Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million.

13 Aug 2018

Orchard raises $150 mln to expand after GSK gene therapy deal

LONDON, Aug 13 Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million.

13 Aug 2018

GlaxoSmithKline appoints HSBC's Iain Mackay as new CFO

LONDON GlaxoSmithKline has named Iain Mackay from global bank HSBC as its new chief financial officer, marking another key appointment by Chief Executive Emma Walmsley as she reshapes the top team at Britain's biggest drugmaker.

07 Aug 2018

GlaxoSmithKline appoints HSBC's Iain Mackay as new CFO

LONDON GlaxoSmithKline has named Iain Mackay from global bank HSBC as its new chief financial officer, marking another key appointment by Chief Executive Emma Walmsley as she reshapes the top team at Britain's biggest drugmaker.

07 Aug 2018

Earnings vs. Estimates